Who is eligible for clinical trial NCT06632327?

Participants must meet the protocol's inclusion criteria for Resectable Lung Non-Small Cell Carcinoma. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06632327 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-20

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer (NCT06632327)

Perioperative Versus Adjuvant Systemic Therapy in Patients With Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Alliance for Clinical Trials in Oncology

🩺 Plain-English Summary (8th-Grade Level)

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (0 items).

Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Histologically or cytologically confirmed surgically resectable stage IIA to IIIB NSCLC according to the American Joint Committee on Cancer (AJCC) 9th edition (stage IIA to IIIB NSCLC up to single station N2, according to the AJCC 8th edition) \* Note: Patients with resectable stage N2a or T4 are eligible, but patients with stage N2b or N3 are not eligible. Patients with known EGFR or ALK alterations are excluded
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (or Karnofsky ≥ 60%)
No prior systemic treatment for NSCLC within 5 years except stage 1 and 2 cancers treated with curative intent
No treatment for another malignancy within 3 years prior to registration, except for stage 1 or 2 cancers treated for curative intent; patients must be disease free for one year prior to registration. Patients with non-melanoma skin cancer, urothelial carcinoma in situ (Tis), noninvasive papillary carcinoma of the urinary bladder (Ta), prostatic intraepithelial neoplasia (PIN), ductal carcinoma in situ (DCIS) of the breast, or cervical intraepithelial neoplasia (CIN) of the uterine cervix are also eligible
No active autoimmune disease, interstitial lung disease, or transplant that precludes safe treatment with immune checkpoint inhibitors
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (411 Sites)

Showing the first 25 of 411 sites.

University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Fairbanks Memorial Hospital — Fairbanks, Alaska
Cancer Center at Saint Joseph's — Phoenix, Arizona
Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Mercy Hospital Fort Smith — Fort Smith, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
CARTI Cancer Center — Little Rock, Arkansas
Kaiser Permanente-Deer Valley Medical Center — Antioch, California
Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
Mercy Cancer Center - Carmichael — Carmichael, California
Mercy San Juan Medical Center — Carmichael, California
Enloe Medical Center — Chico, California
Kaiser Permanente Dublin — Dublin, California
Mercy Cancer Center - Elk Grove — Elk Grove, California
Kaiser Permanente-Fremont — Fremont, California
Fresno Cancer Center — Fresno, California
Kaiser Permanente Fresno Orchard Plaza — Fresno, California
Kaiser Permanente-Fresno — Fresno, California
UC San Diego Moores Cancer Center — La Jolla, California
Fremont - Rideout Cancer Center — Marysville, California
Mercy Cancer Center — Merced, California
Kaiser Permanente- Modesto MOB II — Modesto, California
Kaiser Permanente-Modesto — Modesto, California
Kaiser Permanente Oakland-Broadway — Oakland, California
Kaiser Permanente-Oakland — Oakland, California

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Resectable Lung Non-Small Cell Carcinoma

Explore by condition: All Resectable Lung Non-Small Cell Carcinoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗